
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Medical Oncology Department, 2 Unité Mixte de Recherche 144 Centre National de la Recherché Scientifique, 3 Department of Tumor Biology, and 4 Surgery Department, Institut Curie, Paris, France
Purpose: The presence of tumor cells in bone marrow has been reported to represent an important prognostic indicator in breast cancer, but the clinical significance of circulating cells in peripheral blood is less well known. The aim of this study was to evaluate the feasibility of identifying cytokeratin (CK)-expressing cells in peripheral blood with an automat-assisted immunohistochemical detection system and to compare it with detection of tumor cells in bone marrow samples.
Experimental Design: Cytospun Ficoll fractions of peripheral blood and bone marrow were obtained simultaneously in 114 breast cancer patients at different stages of the disease (I to IV) before treatment with chemotherapy. The pancytokeratin (CK) monoclonal antibody A45-B/B3 (anti-CKs 8, 18, and 19) was used for epithelial cell detection. Immunostained cells were detected by an automated cellular imaging system (ChromaVision Medical System).
Results: CK+ cells were detected in 28 (24.5%) patients in blood and in 67 (59%) patients in bone marrow. Twenty-six (93%) patients with CK-positive cells in blood also had positive bone marrow (P < 0.001). Positive cells were detected in peripheral blood in 3/39 (7.5%) operable breast cancers (stage I/II), 9 of 36 (25%) locally advanced breast cancers (stage III), and 16 of 39 (41%) patients with metastatic disease (stage IV; P = 0.017). In the subgroup of nonmetastatic patients (n = 75), prognostic factors for poor disease-free survival were: absence of estrogen receptor; presence of CK+ cells in bone marrow (P = 0.012); clinical nodal involvement; large tumor size (T4); and presence of tumor emboli. Presence of circulating CK+ cells in the peripheral blood was not statistically correlated with disease-free survival. On multivariate analysis, independent indicators for disease-free survival were: absence of estrogen receptor (P = 0.043) and presence of CK+ cells in bone marrow (P = 0.076).
Conclusions: The clinical relevance of circulating epithelial cells as a prognostic factor is not supported by the present data, especially in comparison with tumor cells in the bone marrow. However, this method of detection may be useful to monitor the efficacy of treatment in advanced or metastatic breast cancer.
This article has been cited by other articles:
![]() |
C. Alix-Panabieres, S. Riethdorf, and K. Pantel Circulating Tumor Cells and Bone Marrow Micrometastasis Clin. Cancer Res., August 15, 2008; 14(16): 5013 - 5021. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cristofanilli, J. Reuben, and J. Uhr Circulating Tumor Cells in Breast Cancer: Fiction or Reality? J. Clin. Oncol., July 20, 2008; 26(21): 3656 - 3657. [Full Text] [PDF] |
||||
![]() |
F.-C. Bidard, A. Vincent-Salomon, S. Gomme, C. Nos, Y. de Rycke, J. P. Thiery, B. Sigal-Zafrani, L. Mignot, X. Sastre-Garau, J.-Y. Pierga, et al. Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse Clin. Cancer Res., June 1, 2008; 14(11): 3306 - 3311. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Vincent-Salomon, F C Bidard, and J Y Pierga Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues J. Clin. Pathol., May 1, 2008; 61(5): 570 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-C. Bidard, A. Vincent-Salomon, B. Sigal-Zafrani, V. Dieras, C. Mathiot, L. Mignot, J.-P. Thiery, X. Sastre-Garau, and J.-Y. Pierga Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells Ann. Onc., March 1, 2008; 19(3): 496 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Scheel, T. Onder, A. Karnoub, R. A. Weinberg, and J. E. Talmadge Adaptation versus Selection: The Origins of Metastatic Behavior Cancer Res., December 15, 2007; 67(24): 11476 - 11480. [Full Text] [PDF] |
||||
![]() |
M. Ignatiadis, N. Xenidis, M. Perraki, S. Apostolaki, E. Politaki, M. Kafousi, E. N. Stathopoulos, A. Stathopoulou, E. Lianidou, G. Chlouverakis, et al. Different Prognostic Value of Cytokeratin-19 mRNA Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5194 - 5202. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Pantel and U. Woelfle Circulating Tumor Cells as an Indicator of Invasion Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 116 - 119. [Full Text] [PDF] |
||||
![]() |
J. T. Kaifi, E. F. Yekebas, P. Schurr, D. Obonyo, R. Wachowiak, P. Busch, A. Heinecke, K. Pantel, and J. R. Izbicki Tumor-Cell Homing to Lymph Nodes and Bone Marrow and CXCR4 Expression in Esophageal Cancer J Natl Cancer Inst, December 21, 2005; 97(24): 1840 - 1847. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Braun, F. D. Vogl, B. Naume, W. Janni, M. P. Osborne, R. C. Coombes, G. Schlimok, I. J. Diel, B. Gerber, G. Gebauer, et al. A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer N. Engl. J. Med., August 25, 2005; 353(8): 793 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Witkiewicz, S. Varambally, R. Shen, R. Mehra, M. S. Sabel, D. Ghosh, A. M. Chinnaiyan, M. A. Rubin, and C. G. Kleer {alpha}-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1418 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Muller, N. Stahmann, S. Riethdorf, T. Rau, T. Zabel, A. Goetz, F. Janicke, and K. Pantel Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity Clin. Cancer Res., May 15, 2005; 11(10): 3678 - 3685. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Braun and B. Naume Circulating and Disseminated Tumor Cells J. Clin. Oncol., March 10, 2005; 23(8): 1623 - 1626. [Full Text] [PDF] |
||||
![]() |
W. J. Allard, J. Matera, M. C. Miller, M. Repollet, M. C. Connelly, C. Rao, A. G. J. Tibbe, J. W. Uhr, and L. W. M. M. Terstappen Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases Clin. Cancer Res., October 15, 2004; 10(20): 6897 - 6904. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |